Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact

New Study to Test Dendritic Cell Immunotherapy Treatment on Mesothelioma

Published on March 25, 2019

A Netherlands-based biotechnology company has announced progress on its phase II/III mesothelioma study, looking at the impact of its dendritic cell therapy on patients diagnosed with the rare and deadly asbestos-caused cancer. Amphera B.V.’s entire focus is on dendritic cell therapy, and is currently planning three different clinical trials: this is its first, which will focus on pleural mesothelioma patients, while its second will look to the effectiveness of the treatment on peritoneal mesothelioma and third has not yet been announced.

Dendritic Cell Therapy Is Based on Vaccine Science

The basic theory behind dendritic cell therapy, whether it is used on mesothelioma or any other cancer, is to create a tailored cancer vaccine that uses a patient’s own cancer to enhance their immunity against its return. By isolating a fragment of mesothelioma and then combining it with blood from the patient which has gone through a special filtering process, the company isolates a part of the immune system that fights cancer. These cells are then exposed to the fragment of the cancer in the lab and then returned to the patient’s body to protect against the cancer’s spread.

Study Recruits 230 Pleural Mesothelioma Patients

Amphera’s phase II/III study is called DENIM, which stands for DENdritic cell Immunotherapy for Mesothelioma. The company has already recruited 230 pleural mesothelioma patients, half of whom will receive 3 bi-weekly injections of the company’s drug MesoPher following chemotherapy, followed by supportive care and then more injections at weeks 18 and 30. The control group will simply receive supportive care. The two groups will be compared for the duration of their overall survival as well as progression free survival. The patients were recruited from several different mesothelioma centers across Europe.

Speaking of the importance of the study, Amphera’s CEO Rob Meijer said, “The number of pleural mesothelioma patients is on the rise and to date there is only one therapy registered with limited clinical benefit. As such, new approaches to treating mesothelioma are much needed to improve the prognosis for these patients.” 

Every day scientists are creating new ways to fight malignant mesothelioma. Though this therapy is still in the testing phases, there are others that are available to provide victims of asbestos-related diseases with improved quality of life and survival times. For more information, contact the Patient Advocates at Mesothelioma.net at  1-800-692-8608.

FREE Mesothelioma Packet

Written by Terri Oppenheimer

Terri Heimann Oppenheimer
Terri Heimann Oppenheimer is the head writer of our Mesothelioma.net news blog. She graduated from the College of William and Mary with a degree in English. Terri believes that knowledge is power and she is committed to sharing news about the impact of mesothelioma, the latest research and medical breakthroughs, and victims’ stories.

Learn more about and contact Terri
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net